Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Br J Haematol. 2017 Jan 5;176(4):583–590. doi: 10.1111/bjh.14451

Table III.

Pharmacokinetic Studies

Sample* Pre-treatment Month 1 Month 2 Month 5 Month 8 Month 12
Retinol
  Peak 1.4 (0.5 – 4.7),
n = 21		 1.3 (0.0 – 3.1),
n = 17		 1.2 (0.4 – 2.9),
n = 10		 1.4 (0.6 – 2.3),
n = 7		 1.2 (0.0 – 15.6),
n = 5
  Trough 0.5 (0.0 – 2.3),
n = 18		 0.5 (0.0 – 2.0),
n = 21
Plasma fenretinide
  Peak 12.9 (0.7 – 33.5),
n = 18		 14.9 (0.3 – 26.1),
n = 21
  Trough 2.6 (0.0 – 6.9),
n = 7		 3.4 (0.3 – 10.5),
n = 17		 3.4 (0.6 – 7.7),
n = 10		 3.9 (0.3 – 9.5),
n = 7		 3.3 (1.0 – 26.4),
n = 6
Trough bone
marrow
fenretinide		 5.2 (0.0 – 14.9),
n = 14		 4.8 (2.0 – 12.6),
n = 9		 2.5 (1.7 – 15.4),
n = 7		 6.2 (1.3 – 21.5),
n = 5
*

All samples are the median value in µM, (range), with n denoting the number of subjects with available testing